CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Cytek Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$5.25+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $679.67M
- P/E (TTM)
- –
- Dividend yield
- –
Cytek Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product | $144.23M | $153.26M | $156.72M | $148.60M | $119.52M | $85.28M | 71.6% | -5.9% |
| Service | $57.26M | $47.19M | $36.30M | $15.44M | $8.43M | $7.56M | 28.4% | +21.3% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| United States | $95.25M | $92.61M | $102.09M | $94.59M | $72.72M | $55.48M | 47.3% | +2.9% |
| EMEA | $55.88M | $62.34M | $53.18M | $43.96M | $36.97M | $25.91M | 27.7% | -10.4% |
| APAC | $41.08M | $35.77M | $31.60M | $22.52M | $16.08M | $10.74M | 20.4% | +14.8% |
| China | $20.50M | – | – | – | – | – | 10.2% | – |
| Other | $9.28M | $9.73M | $6.15M | $2.96M | $127.95M | $92.84M | 4.6% | -4.6% |
From the segment and revenue-disaggregation notes of Cytek Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.